Vanguard Global Advisers
LXEO icon

Vanguard Global Advisers’s Lexeo Therapeutics LXEO Stock Holding History

Vanguard Global Advisers’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Sell
23,385
-19,190
-45% -$104K ﹤0.01% 2740
2026
Q1 		$244K Buy
+42,575
New +$302K ﹤0.01% 2340

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Global Advisers's LXEO Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Lexeo Therapeutics (LXEO) stake by 45% in Q2 2026, selling an estimated $104K and leaving 23,385 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #2740.

Vanguard Global Advisers first reported a position in LXEO in Q1 2026 and has held it in 2 quarters since. The position peaked at $244K in Q1 2026. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Vanguard Global Advisers held 23,385 shares of Lexeo Therapeutics worth $109K as of Q2 2026.
  • Vanguard Global Advisers sold 19,190 Lexeo Therapeutics shares in Q2 2026, an estimated $104K.
  • Lexeo Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2740 holding.
  • Vanguard Global Advisers first reported a position in Lexeo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Lexeo Therapeutics position peaked at $244K in Q1 2026.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.